The Financial Reality of Bispecific Antibodies: What It Takes to Build and Sustain a Program
As oncology therapies become increasingly complex and high cost, cancer programs are being pushed to rethink how financial, operational, and clinical decisions come together in practice. In this episode, CANCER BUZZ sits down with Sarah Hudson-DiSalle, Assistant Director of Infusion Reimbursement Services, to explore the real-world financial landscape of bispecific antibodies (BsAbs), focusing on how organizations evaluate readiness, navigate uncertainty, and manage financial risk. Through a practical, system-level lens, this conversation highlights where challenges emerge, how institutions…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.